FAQ

brentuximab vedotin

Known as: CAC10-1006, cAC10-vcMMAE 
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
05010020032018

Related topics

Related topics

4 relations

Narrower (2)

AdcetrisSGN-35
ImmunoconjugatesTumor Necrosis Factor Receptor Superfamily Member 8, human

Related mentions per year

Related mentions per year

1983-2018
19801990200020102020
brentuximab vedotin
Immunoconjugates
Tumor Necrosis Factor Receptor Superfamily Member 8, human
SGN-35
Adcetris

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express CD30. This phase 2… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2015
2015
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
BACKGROUND Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Brentuximab vedotin.
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30(+) malignancies, including… (More)
Is this relevant?
2014
2014
Blood Spotlight Brentuximab vedotin
Delivery of cytotoxic agents specifically to malignant cells has always been a goal of cancer therapy. With the development of… (More)
Is this relevant?
2012
2012
Brentuximab vedotin
In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Hodgkin lymphoma (HL) relapsing after allogeneic stem cell transplantation (alloSCT) presents a major clinical challenge. In the… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
BACKGROUND Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous… (More)
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?